D75.822
Immune-mediated heparin-induced thrombocytopenia
Clinical Classification Guidelines
Inclusion Terms
- Immune-mediated HIT
- Type 2 heparin-induced thrombocytopenia
Medical Intelligence & Overview
Immune-mediated heparin-induced thrombocytopenia (HIT), classified under ICD-10 code D75.822, is a rare but serious immune system response triggered by heparin therapy. This condition is a form of type 2 HIT, characterized by a significant decrease in platelets due to immune reactions. While heparin is commonly used as an anticoagulant in various medical settings, this adverse immune response can cause dangerous blood clot formation and other complications. Recognizing and understanding this condition is crucial for healthcare providers and patients receiving heparin treatment.
Causes & Symptoms
Clinical Causes: Use of heparin, especially when administered in high doses or over an extended period Development of antibodies against the heparin-platelet factor 4 (PF4) complex An immune response that mistakenly targets the body's own platelets when exposed to heparin
Key Symptoms: Sudden drop in platelet count (thrombocytopenia) Formation of blood clots in veins or arteries, leading to increased risk of deep vein thrombosis or pulmonary embolism Skin reactions such as redness, rash, or skin necrosis at heparin injection sites Symptoms of blood clots, including pain, swelling, or warmth in affected limbs Potential development of stroke, heart attack, or limb ischemia due to clot formation
Diagnostic & Treatment
Diagnosis Path: The diagnosis of immune-mediated HIT involves a combination of clinical assessment and laboratory testing. Healthcare providers typically evaluate the timing of platelet count decline in relation to heparin exposure, look for signs of clotting, and conduct specific blood tests. These tests include immunoassays to detect antibodies against the heparin-PF4 complex, as well as functional assays to assess platelet activation in response to patient serum.
Treatment Protocols: Management of immune-mediated HIT requires immediate discontinuation of all heparin products. Alternative non-heparin anticoagulants, such as direct thrombin inhibitors or factor Xa inhibitors, are often used to prevent and treat thrombosis. Supportive care may include platelet transfusions in severe cases, although caution is advised. Close monitoring of blood counts and clinical signs is essential during treatment. The goal is to prevent clot formation while avoiding further immune reactions.
Clinical Advice & FAQs
Billing Guidance
Is D75.822 a billable ICD-10 code?
Yes, D75.822 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D75.822?
Clinical documentation must specify the nature of Immune-mediated heparin-induced thrombocytopenia and any associated comorbidities for accurate reporting.
Cite this Clinical Reference